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Abstract
Genome instability is regarded as a hallmark of cancer. Human tumors frequently carry clonally expanded mutations in their
mitochondrial DNA (mtDNA), some of which may drive cancer progression and metastasis. The high prevalence of clonal
mutations in tumor mtDNA has commonly led to the assumption that the mitochondrial genome in cancer is genetically
unstable, yet this hypothesis has not been experimentally tested. In this study, we directly measured the frequency of non-
clonal (random) de novo single base substitutions in the mtDNA of human colorectal cancers. Remarkably, tumor tissue
exhibited a decreased prevalence of these mutations relative to adjacent non-tumor tissue. The difference in mutation
burden was attributable to a reduction in C:G to T:A transitions, which are associated with oxidative damage. We
demonstrate that the lower random mutation frequency in tumor tissue was also coupled with a shift in glucose
metabolism from oxidative phosphorylation to anaerobic glycolysis, as compared to non-neoplastic colon. Together these
findings raise the intriguing possibility that fidelity of mitochondrial genome is, in fact, increased in cancer as a result of a
decrease in reactive oxygen species-mediated mtDNA damage.
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Introduction
Genetic heterogeneity is an important feature of human
cancers. The ongoing introduction of rare somatic mutations into
the genome of each cell within a developing tumor provides the
necessary genetic diversity to fuel the adaptive evolution that
drives disease progression [1]. Among the many random
mutations that arise in an evolving cancer, only a small fraction
will confer their host cell with a neoplastic advantage. Those that
do, however, may undergo positive selection and clonally
proliferate until they, and their resulting phenotype, drive
continued tumor progression.
A preponderance of evidence points to the importance of
acquired genetic instability in the nuclear genome as a key
facilitator of tumorigenesis [2]. Far less attention, however, has
been paid to alterations in replication fidelity of the mitochondrial
genome. Mitochondria are semi-autonomous entities with a
unique biology whose genomic replication is independent of the
cell cycle and accomplished with a distinct complement of
enzymatic machinery [3]. Over the last decade, multiple
sequencing efforts have revealed that the mitochondrial genomes
of human tumors frequently carry clonally expanded mtDNA
mutations [4,5]. Mounting evidence indicates that a subset of these
mutations directly contributes to cancer progression by accelerat-
ing primary tumor growth [6] and conferring metastatic potential
[7] to tumor cells.
An open question remains as to whether the nuclear point
mutation instability of human cancers [8] is recapitulated in the
mitochondrial genome. Understanding mitochondrial mutagenesis
in normal and tumor cells will further delineate a fundamental
process in cancer progression and potentially identify novel
mitochondrial targets for cancer prevention, treatment and early
diagnosis. In this study, we address this question by using the high-
sensitivity of the Random Mutation Capture (RMC) assay [9,10]
to directly measure the frequency of non-clonal (random) mtDNA
mutations in normal and colorectal cancer tissues.
Results
Clonal mutations represent identical mutant mtDNA molecules
that are present in the majority of genomes within a cell
population. Such mutations occur via propagation of the genotype
of a single mutant genome in a single founder cell to all cellular
descendants during clonal proliferation. In a tumor, clonal
mutations reflect the genotype of the founding cell of the terminal
clonal outgrowth. Random mutations, in contrast, are mutations
that arise in cell divisions after the founding of a clonal population
and are present in only a subset of cells. The frequency of random
mutations in a population is proportional to the rate of mutation
and dependent on the number of cell divisions having led to the
generation of the sampled population.
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First, to stratify our colorectal tissue samples with respect to the
abundance of clonally expanded mutations, we sequenced the
entire mitochondrial genome of each of our samples. We found
that 55% (11 of 20) of the carcinomas carried at least one clonally
expanded mutation in their mtDNA (Table 1). Furthermore, when
located inside a protein-coding gene, the mutations identified in
our tumors uniformly resulted in frameshift mutations (2/13) or
non-synonymous changes (11/13). Although the observed fre-
quency of non-synonymous point mutations (11/11) exceeded that
expected by chance, the difference did not reach significance in
our sample set (P = 0.06, 2-tailed chi-square test, n = 11). To assess
whether the expansion of mtDNA mutations is an early or a late
event during carcinogenesis, we also sequenced the entire
mitochondrial genome of 19 patient-matched adenomas. We
found that 32% (6 of 19) of the adenomas carried clonally
expanded mutations (Table 1), revealing that clonal expansion of
mtDNA mutations can occur prior to overt malignancy.
Next, we quantified the frequency of random mutations in
colorectal tissue using the RMC assay. We found that in normal
colorectal tissue, mutations occurred at an average absolute
frequency of 3.260.561025 per base pair at a site in the 12S
rRNA subunit (Figure 1A), and 1.260.261024 at a second site in
the COXI gene (Figure 1B). At both sites, mutation frequency was
independent of patient age (Figure 2A). Unexpectedly, when we
examined patient-matched colorectal carcinomas we found that,
on average, tumor cells displayed an approximately three-fold
lower random mutation frequency compared to normal colonic
tissue (1.460.461025, P = 0.004 for 12S rRNA, 4.161.261025,
P,0.001 for COXI, 2 tailed paired t-test) (Figure 1A–1B). No
appreciable difference in mtDNA copy number was observed
between the tissues (Figure 2B). These mtDNA findings are in
stark contrast to previous observations in which we demonstrated
a.100-fold increase in the frequency of random mutations in the
nuclear DNA of human tumors [11].
The frequency of random mutations within a tissue is proportional
to both the rate of de novo mutations per generation and the total
number of cell divisions having occurred during development and
aging. The observed decrease in mutation frequency within tumors
could, thus, either be the result of a reduced mutation rate during
tumor growth, or simply a consequence of the fact that the number
of cell divisions having occurred since founding of the final clonal
tumor outgrowth may be fewer than the number having occurred
between development and sampling of normal adult colon tissue
[12]. Genetic bottlenecking during the clonal formation of a
carcinoma from a single founder cell effectively purges mutational
diversity that has accumulated in normal colonic mucosa over a
lifetime by repopulating it with closely related progeny [13].
Table 1. Clonal Mitochondrial DNA Mutations Identified in
Colorectal Tissue.
Patient ID Tissue Gene DNA Protein
2 Carcinoma COXII 7859G.A D92N
COXIII 9451G.A G82E
4 Carcinoma non-coding 5894insC
Cyt b 15375G.A G210E
5 Carcinoma D-loop 508A.G
6 Carcinoma COXIII 9645G.A A147T
7 Carcinoma D-loop 523delAC
12S rRNA 1598G.A
ND2 4707C.T L80F
10 Carcinoma ND4L 10675G.A C69Y
ND5 13239C.A I301M
D-loop 16465C.T




17 Carcinoma ND5 12426insA frameshift
D-loop 16298C.T
D-loop 16390G.A
18 Carcinoma ND1 3745G.A A147T
ND5 13133delT frameshift
19 Carcinoma ND5 13970G.A S545N
20 Carcinoma D-loop 524insAC
16S rRNA 2957G.A
18 Adenoma ND5 13193T.C L286P





20 Adenoma D-loop 524insAC
16S rRNA 2957G.A
69 Adenoma ND1 3571insC frameshift
ND2 5450C.T
70 Adenoma tRNA M 4465T.C
Cyt b 15448C.T







Mitochondria are the intracellular organelles responsible
for energy production in eukaryotic cells. They are unique
in that they contain their own DNA (mtDNA), which
encodes genes important for mitochondrial function and is
the cell’s only genetic material stored outside the nucleus.
Mutations in both nuclear and mtDNA are believed to
have a role in tumor growth and metastasis. While it is well
established that nuclear DNA has an increased overall
burden of mutations in human cancers, this has not been
investigated in mtDNA. Here we use a highly sensitive
assay to determine mutational load in mtDNA isolated
from patient-matched normal and cancerous colonic
tissues. Surprisingly, we discovered that the frequency of
mutations in mtDNA is actually decreased in tumors
relative to healthy tissues, suggesting that, unlike in
nuclear DNA, accelerated mutagenesis in mtDNA does
not facilitate a cancer’s development and may even hinder
it. These findings raise the possibility that mitochondrial-
targeted cancer therapeutics focused on directly increas-
ing mtDNA damage and mutation might effectively
suppress malignant growth.
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To assess whether clonal expansion alone might account for the
decreased mutation load associated with tumor mtDNA, we
quantified the frequency of random mutations in adenoma tissues.
Advanced adenomas are generally believed to be clonally derived
[14], and the presence of clonal mtDNA mutations empirically
demonstrates this to be true in at least 32% of our samples (Table 1).
Given this, if clonal expansion alone were to underlie the decrease in
random mutation burden, we would expect the frequency of random
mutations in adenoma mtDNA (4.962.361025 per base pair for
12S RNA, and 1.760.661024 for the COXI gene) to be lower than
that of patient-matched normal colon mtDNA (3.260.561025 per
base for 12S rRNA and 1.260.261024 at the COXI gene), but this
was not the case (Figure 2C) (P = 0.73 for 12S RNA and P = 0.15 for
the COXI gene, 2-tailed paired t-test). Moreover, the decrease in the
level of genetic heterogeneity in tumors was independent of whether
or not the cancers bore a separate clonal mutation (Figure 2D). Thus,
this leaves the possibility of a reduction in mtDNA mutation rate
during late tumorigenesis.
To gain further insight into possible mechanisms responsible for
reducing mtDNA mutagenesis in tumor cells, we examined the
Figure 1. Decreased Random Mitochondrial DNA Mutations in Colorectal Cancer. (A) Mutation frequency (6 s.e.m.) was determined at
TaqI restriction sites 1215–1218 within the 12S rRNA gene and (B) 7335–7338 within the COXI gene in mitochondrial DNA isolated from patient-
matched normal (blue) and carcinoma (red) colorectal tissues. The mean (n = 20) mutation burden (6 s.e.m.) of mtDNA isolated from carcinoma
versus normal tissue is reduced ,3-fold at both mutational target sites. * P,0.01; ** P,0.001; two-tailed paired t-test.
doi:10.1371/journal.pgen.1002689.g001
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Figure 2. Random Mitochondrial DNA Mutations and Genome Copy Number in Colorectal Tissue. (A) Frequency of mitochondrial
mutation as a function of age. Mutation frequency was determined at the 12S rRNA gene (blue) and COXI gene (red) in mtDNA isolated from normal
human colorectal tissue. Each data point represents one patient. (B) Mitochondrial genome content (6 s.e.m.) in normal and tumor tissue. (C)
Average frequency of random mitochondrial mutations in colorectal tissue. Mean (6 s.e.m.) mutation frequency within the 12S rRNA gene and COXI
gene in mtDNA isolated from patient-matched normal (n = 20), adenoma (n = 8), and carcinoma (n = 20) colorectal tissues. (D) Patient-matched
comparison of the mean (6 s.e.m.) mtDNA random mutation frequency as stratified by carcinomas that harbored one or more clonal mutation.
doi:10.1371/journal.pgen.1002689.g002
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mutation spectrum of 796 random mutation events (297 normal,
275 adenoma, 224 carcinoma). We found that in normal and
adenoma tissues, C:G to T:A transitions predominated (Figure 3).
Similar spectra have been previously reported in mice and are
consistent with deamination of cytosine bases as the primary
source of mutagenesis [10], a process that is driven by oxidative
damage [15]. While all tissue types exhibited similar levels of T:A
to C:G mutations, there was .3-fold decrease in C:G to T:A
transitions among the tumor samples relative to normal colon,
suggesting the source of these latter oxidatively-mediated muta-
tions to be specifically reduced during carcinoma outgrowth.
Interestingly, the majority of the clonally expanded mutations
observed in carcinomas are C:G to T:A transitions (Table 1),
which is similar to that previously reported in human colorectal
tumors [16] and to the spectrum of random mutations in normal
and adenoma tissue (Figure 3A), but is markedly different from the
spectrum of mutations generated by polymerase c on undamaged
template [17,18,19]. This suggests that the biological change
responsible for reducing the frequency of C:G to T:A mutations
occurs after the initiation of neoplastic clonal expansion.
One of the biochemical hallmarks of tumor cells involves the
reprogramming of energy metabolism from primarily oxidative
phosphorylation (OXPHOS) to anaerobic glycolysis [20], a
phenomenon termed the Warburg effect [21]. This transition
effectively decreases OXPHOS, and by extension, the production
of reactive oxygen species (ROS) in the mitochondrial matrix,
which have the potential to damage mtDNA [22]. To investigate
whether the switch between oxidative phosphorylation and
glycolysis is associated with a change in mtDNA mutation
frequency, we analyzed the relative expression of protein markers
for glycolysis and oxidative phosphorylation (Figure 4A). Consis-
tent with an upregulation of glycolysis, we observed a significant
increase in the glycolytic markers pyruvate kinase (PK) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) [23] in
tumors relative to normal colon (Figure 4B). Moreover, as assessed
by the abundance of the catalytic subunit OXPHOS marker ATP
synthase (ß-F1-ATPase) [23,24] normalized to the structural
mitochondrial protein Hsp60, mitochondrial bioenergetic compe-
tence (i.e. OXPHOS) [25,26,27] is significantly decreased in colon
carcinoma compared to normal controls (Figure 4C) (P,0.05, 2-
tailed paired t-test). As such, the BioEnergetic Cellular (BEC)
index, which gives the ratio of OXPHOS protein content to
glycolytic protein content [26,27], is reduced and consistent with a
shift to Warburg metabolism in tumor tissue (Figure 4D) (P,0.05,
2-tailed paired t-test). In addition, to generate an instantaneous
snapshot of the competing forms of glucose metabolism, we
directly measured the relative amount of citrate and lactate in
colorectal tissues by gas chromatography/mass spectrometry
(GC/MS). We found that citrate, a tricarboxylic acid (TCA) cycle
intermediate that correlates tightly with the level of mitochondrial
respiration [28,29], was significantly reduced in carcinomas
relative to normal colon (Figure 4E) (P,0.01, 2-tailed paired t-
test), whereas the level of lactate, the end product of anaerobic
glycolysis [30], was increased (Figure 4E) (P,0.05, 2-tailed paired
t-test).
Finally, to examine the relationship between energy metabolism
and mtDNA mutation frequency, we plotted the random mutation
frequency of all samples against the ratio of citrate to lactate
(Figure 5). We found that in both normal and tumor tissue,
mutation frequency decreases concomitantly with reduced mito-
chondrial respiration (linear regression: slope 210.1760.9894,
significance of non-zero slope P,0.0001, R2 = 0.71). This is
consistent with the hypothesis that a large fraction of mtDNA
mutagenesis is a consequence of oxidative damage generated as a
byproduct during OXPHOS and provides a plausible rationale for
the decreased frequency of random mutations in tumor cells–
specifically, a decrease in C:G to T:A transitions (Figure 3), the
most commonly observed mutations resulting from oxidative
damage [15].
Discussion
The experiments described here expose a surprising paradox in
cancer biology. It has long been recognized that genomic
instability is a hallmark of cancer cells. Whether instability is a
driving force or an indirect consequence of cancer progression
remains as contentious today as it was three decades ago
[31,32,33]. The data presented above suggest that a mutator
phenotype does not extend to the mitochondria and, in fact,
mtDNA mutagenesis at the level of single base substitutions is
suppressed within human colorectal tumors. While cells that
acquire an increased rate of nuclear mutagenesis may be selected
for to facilitate efficient generation of selectable genetic variants
necessary for neoplastic evolution, no such pressures appear to
exist for the mitochondrial genome.
Our data indicate that reduced mtDNA genetic diversity does
not limit tumor progression, and that normal mtDNA mutation
rates may actually serve as a barrier to cancer development. In
Figure 3. Decreased mtDNA Mutagenesis in Colorectal Carci-
noma Is Attributable to a Reduction in C:G to T:A Transitions.
Mitochondrial DNA mutation spectrum (6 s.e.m.) per Mb in human
colorectal tissue. Mutant mtDNA amplicons (n = 796) spanning two
restriction sites (1215–1218 and 7335–7338) were recovered from the
RMC assay and subjected to DNA sequencing to generate the
mutational signature of mtDNA isolated from normal (n = 297),
adenoma (n = 275), and carcinoma (n = 224) colorectal tissues. *
P,0.0001; two-tailed paired t-test.
doi:10.1371/journal.pgen.1002689.g003
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support of this hypothesis is the large body of evidence espousing
the mitochondrial theory of aging [34,35,36]. In this model, ROS
production, mtDNA damage, mutation, and respiratory chain
dysfunction are linked in a self-perpetuating cycle that generates a
progressive decline of mitochondrial function, eventually impair-
ing cell physiology and viability. In this context, a decrease in
mtDNA mutagenesis secondary to a reduction in ROS might
favor disease progression by breaking this cycle, and thereby
contributing to the development of tumor cell immortality. By
extension, it is conceivable that mitochondrial targeted cancer
therapeutics focused on directly increasing mtDNA damage might
efficiently suppress malignant growth. For example, reactivating
tumor mitochondrial metabolism to increase mtDNA mutagenesis
by pharmacologic measures, or developing mutagenic drugs with




Ethical approval was granted by the St. Vincent’s Hospital
Ethics and Medical Research Committee to conduct all aspects of
this study in accord with the principles expressed in the
Declaration of Helsinki.
Tissues and DNA isolation for mutational analysis
This study included 21 colorectal cancer patients (median age
72 years; range 52–85 years; 8 men, 13 women) treated surgically
in the Centre for Colorectal Disease, St. Vincent’s University
Hospital, Dublin, Ireland. Tumor and matched normal mucosa
were available for all cases. Tumors were staged using the WHO
classification. There were 2 Stage I, 11 Stage II, 7 Stage III and 1
Stage IV cancers. 11/20 of these cases also had matched adenoma
tissue. An additional 8 cases had adenoma and matched normal
tissue (median age 69.5 years; range 59–83 years; 5 male, 3
female). Tissues collected were snap frozen and stored at 280 C.
Tissue samples (,200 mg) were immersed in 5 mL homogeni-
zation medium (0.32 M sucrose, 1 mM EDTA, 10 mM Tris-HCl,
pH 7.8) and disrupted with a glass Dounce-type homogenizer.
The homogenate was transferred to a 15 mL tube and centrifuged
at 1000 g for 10 min to isolate the nuclei and cell debris, followed
by centrifugation of the supernatant at 13000 g for 20 min to
pellet the mitochondria. The mitochondrial pellet was resus-
pended in 600 mL lysis buffer (10 mM Tris-HCl, pH 8.0, 150 mM
NaCl, 20 mM EDTA, 1% SDS, and 0.2 mg/ml Proteinase K)
and incubated at 55uC for 1 hr. MtDNA was isolated by phenol-
chloroform extraction followed by isopropanol precipitation.
mtDNA RMC assay
MtDNA was diluted and digested with 100 units TaqI restriction
enzyme (New England Biolabs), 100 mg/mL BSA and a TaqI-
specific digestion buffer (10 mM Tris-HCl, 10 mM MgCl2,
100 mM NaCl, pH 8.4) for 5 hrs, with 100 units TaqI added
each hour. Mutation frequencies were determined for TaqI-
digested mtDNA via real-time PCR in two separate reactions, one
with a primer set flanking the TaqI restriction site to quantify the
number of mutant molecules (i.e., those molecules resistant to
digestion) and one with a set of primers in a region without a TaqI
restriction site to quantify the total number of molecules. PCR was
performed in triplicate in 25 mL reaction volumes, with 12.5 mL
Figure 4. Metabolic Shift in Human Colorectal Cancer. (A) Western blot analysis of the expression levels of markers of oxidative
phosphorylation (ß-F1-ATPase), structural function of the mitochondria (Hsp60), and the glycolytic pathway [GAPDH and pyruvate kinase (PK)],
fractionated by SDS-PAGE and blotted with the corresponding antibodies from eight patient-matched normal (N) and tumor (T) human colorectal
tissues. (B) The comparative cellular content of each glycolytic protein marker relative to the expression of tubulin in normal (blue) and tumor (red)
tissue. (C) The bioenergetic competence of the mitochondria (ß-F1-ATPase/Hsp60 ratio) from tissues, and (D) overall mitochondrial potential of the
cell, defined as the BioEnergetic Cellular Index (BEC index). BEC index is assessed by the ß-F1-ATPase/Hsp60/GAPDH ratio, providing a normalized
proteomic evaluation of the metabolic shift in colorectal tumors. (E) Gas chromatography/mass spectrometry (GC/MS) metabolite analysis revealing
significantly higher levels of lactate and lower levels of citrate in cancer tissues when compared to patient-matched normal colorectal tissue controls.
Decreased citrate in tumors indicates reduced flux through the tricarboxylic acid cycle. Coupled with increased lactate levels, these metabolic
alterations are consistent with a shift in glucose metabolism from oxidative phosphorylation (OXPHOS) to glycolysis among tumors. Box and whisker
plots depict the median, distribution, and data range. The median is indicated by the black line, the box shows the interquartile range, and the ends
of the whiskers the maxima and minima. * P,0.05; ** P,0.01.
doi:10.1371/journal.pgen.1002689.g004
Figure 5. Decreased mtDNA Mutagenesis Is Coupled to a Shift
in Glucose Metabolism. Normal (blue) and tumor (red) patient-
matched colorectal tissue comparison of the mean mtDNA mutation
burden (6 s.e.m.) as a function of the tissue metabolic signature. This
plot illustrates the inverse correlation between the level of mitochon-
drial respiration and mutagenesis (linear regression with 95% confi-
dence intervals, slope 210.1760.9894, significance of non-zero slope
P,0.0001, R2 = 0.71).
doi:10.1371/journal.pgen.1002689.g005
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Brilliant SYBR Green QPCR Master Mix (Stratagene), 1 unit
UDG (NEB), 1 mL of 25 mM forward and reverse primers, and
diluted TaqI-digested mtDNA.
Mutant molecules were confirmed resistant to TaqI cleavage by
post-PCR restriction digest and by sequencing. Amplicons were
cloned into the pCR4-TOPO TA vector (Invitrogen) following the
kit’s instructions, and the resulting clones were transformed into
DH5 alpha-T1R cells. The cells were plated on LB agar media
supplemented with 50 mg/mL kanamycin and grown at 37uC
overnight. Single colonies were picked into 1 mL LB media with
10% glycerol and incubated at 37uC for 16 hrs. These cultures
were frozen and sent to the University of Washington High
Throughput Genomics Center for rolling circle amplification and
capillary sequencing.
mtDNA copy number quantification
To obtain whole DNA (without mitochondrial enrichment),
tissue samples (,50 mg) were immersed in 5 mL homogenization
medium (0.32 M sucrose, 1 mM EDTA, 10 mM Tris-HCl,
pH 7.8) and disrupted with a glass Dounce-type homogenizer.
The homogenate was transferred to a 15 mL tube and centrifuged
at 13000 g for 20 minutes. The pellet was resuspended in 3 mL
lysis buffer (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 20 mM
EDTA, 1% SDS, and 0.2 mg/ml Proteinase K) and incubated at
55uC for 3 hr. DNA was isolated by phenol-chloroform extraction
followed by isopropanol precipitation.
The mtDNA content per cell was determined via real-time PCR
in two separate reactions, one with a primer set to mitochondrial
DNA (ACCACAGTTTCATGCCCATCGT and TTTATGGG-
CTTTGGTGAGGGAGGT) to quantify mitochondrial genomes,
and one with a primer set to the single copy nuclear ß-globin gene
(GTGAAGGCTCATGGCAAGAAAG and TGTCACAGTG-
CAGCTCACTCAGT) to quantify nuclear genomes. Dilution
curve controls demonstrated primer sets to be of equal amplifi-
cation efficiency across a large range of template inputs. PCR was
performed in duplicate in 25 mL reaction volumes, with 12.5 mL
Brilliant SYBR Green QPCR Master Mix (Stratagene), 1 unit
UDG (NEB), 1 mL of 25 mM forward and reverse primers, and
diluted whole genomic DNA.
Mitochondrial genome DNA sequencing
The entire mitochondrial genome was sequenced in the normal,
adenoma, and carcinoma colorectal samples from each patient by
first PCR amplifying the mtDNA with 28 pairs of primers, as
previously described [37]. Clonally expanded mutations were
scored only when the sequence of the adenoma or carcinoma
mtDNA differed from that of the normal colorectal tissue. All
regions with detected mutations were reamplified and sequenced
to rule out the possibility of the mutations being produced by
polymerase errors during the PCR or sequencing processes. In
addition, to guard against the sample mix-up and contamination
that has confounded many mtDNA mutation studies [38], we
compared sequences of patient-matched tissues to the revised
Cambridge Reference Sequence (rCRS) to confirm they shared
common polymorphisms.
SDS-PAGE and Western blot analysis
Total proteins were extracted from frozen tissue using an
AllPrep DNA/RNA/Protein Kit (Qiagen) and dissolved in 8 M
urea (Sigma). Protein preparations were diluted in Laemmli
sample buffer (Bio-Rad; Hercules, CA) and subsequently incubat-
ed at 46uC for 10 min. Next, samples were loaded onto a 10%
MiniProtean TGX precast gel (Bio-Rad) along with a protein
marker (Bio-Rad). The gel was run with Tris-glycine-SDS buffer
(Bio-Rad) for ,38 min at 200 V, followed by blotting onto an
Immun-Blot PVDF membrane (Bio-Rad) in Tris-glycine buffer
(25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3) for
60 min at 100 V at 4uC.
For Western blots, membranes were washed in TBST (TBS,
0.05% Tween 20) and incubated in blocking buffer (TBST
containing 0.5% Tween 20 and 5% dried milk) for 45 min on a
shaker. After blocking, the membranes were probed with primary
antibodies at 4uC overnight. The membrane was washed and then
incubated with secondary antibodies at room temperature for 1 h.
Immunoreactive proteins were developed with the Super Signal
West Pico enhanced chemiluminescence kit (Thermo Sci.) and
exposed onto CL-XPosure Film (Thermo Sci.). Films were imaged
with a CCD camera detection system and analyzed using Quantity
One (Bio-Rad). Protein expression levels were defined as the sum
of the intensities of the pixels inside the volume boundary6the
area of a single pixel (in mm2), normalized with local background
subtraction.
The following antibodies were used: goat polyclonal anti-Atp5B
(C-20) (1: 1000, Santa Cruz Biotech; Santa Cruz, CA), mouse
monoclonal anti-Hsp60 (H-1) (1:1000, Santa Cruz Biotech),
mouse monoclonal anti-GAPDH (6C5) (1:3000, Abcam; Cam-
bridge, MA), and goat polyclonal anti-pyruvate kinase (1:1000,
Abcam). Mouse horseradish peroxidase-conjugated anti-mouse
and anti-goat were used as secondary antibodies (Vector Labs;
Burlingame, CA). Tubulin was used as a loading control and was
detected using a mouse monoclonal anti-ß-tubulin antibody
(1:1000, Invitrogen; Carlsbad, CA).
Sample preparation for metabolic characterization
The sample preparation process was carried out using the
automated MicroLab STAR system from Hamilton Company.
Recovery standards were added prior to the first step in the
extraction process for QC purposes. Sample preparation was
conducted using a Metabolon proprietary series of organic and
aqueous extractions to remove the protein fraction while allowing
maximum recovery of small molecules. The resulting extract was
divided into two fractions; one for analysis by LC and one for
analysis by GC. Samples were placed briefly on a TurboVap
(Zymark) to remove the organic solvent. Each sample was then
frozen and dried under vacuum.
Gas chromatography/mass spectrometry (GC/MS)
The samples destined for GC/MS analysis were re-dried under
vacuum desiccation for a minimum of 24 hours prior to being
derivatized under dried nitrogen using bistrimethyl-silyl-triflour-
oacetamide (BSTFA). The GC column was 5% phenyl and the
temperature ramp was from 40u to 300uC in a 16 minute period.
Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-
scanning single-quadrupole mass spectrometer using electron
impact ionization. The instrument was tuned and calibrated for
mass resolution and mass accuracy on a daily basis. The
information output from the raw data files was automatically
extracted as below.
Bioinformatics
The informatics system consisted of four major components, the
Laboratory Information Management System (LIMS), the data
extraction and peak-identification software, data processing tools
for QC and compound identification, and a collection of
information interpretation and visualization tools for use by data
analysts. The hardware and software foundations for these
informatics components were the LAN backbone, and a database
server running Oracle 10.2.0.1 Enterprise Edition.
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Metabolic compound identification
Compounds were identified by comparison to library entries of
purified standards or recurrent unknown entities. Identification of
known chemical entities was based on comparison to metabolomic
library entries of purified standards. The combination of
chromatographic properties and mass spectra gave an indication
of a match to the specific compound or an isobaric entity.
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